Demographics and transplant characteristics among day 100 HCT survivors in the PET and LET cohorts
| Variables . | Categories . | PET cohort (n = 2155) . | LET cohort (n = 314) . | P value . |
|---|---|---|---|---|
| Age at transplant, y | Median (range) | 48.9 (0.1-80.9) | 55.7 (18.6-78.2) | <.001 |
| Age at transplant, y | 0-11 | 199 (9%) | 0 (0%) | <.001 |
| 12-17 | 132 (6%) | 0 (0%) | ||
| 18+ | 1824 (85%) | 314 (100%) | ||
| Donor age at transplant, y | Median (range) | 36.2 (0.2-78.0) | 31.1 (17.1-72.2) | <.001 |
| Sex | Female | 1009 (47%) | 148 (47%) | .917 |
| Male | 1146 (53%) | 166 (53%) | ||
| Race | White | 1721 (80%) | 250 (80%) | .079 |
| American Indian or Alaska Native | 48 (2%) | 4 (1%) | ||
| Asian | 186 (9%) | 37 (12%) | ||
| Black or African American | 58 (3%) | 10 (3%) | ||
| Native Hawaiian or other Pacific Islander | 32 (1%) | 6 (2%) | ||
| Multiple | 54 (3%) | 6 (2%) | ||
| Unknown | 56 (3%) | 1 (0%) | ||
| Underlying disease | Acute lymphoblastic leukemia | 284 (13%) | 51 (16%) | <.001 |
| Acute myeloid leukemia/myelodysplastic syndrome | 1045 (48%) | 177 (56%) | ||
| Chronic lymphoid malignancies | 375 (17%) | 11 (4%) | ||
| Chronic myeloid malignancies | 258 (12%) | 57 (18%) | ||
| Nonmalignant diseases | 180 (8%) | 18 (6%) | ||
| Other | 13 (1%) | 0 (0%) | ||
| Number of prior transplants | 1 | 1907 (88%) | 304 (97%) | <.001 |
| >1 | 248 (12%) | 10 (3%) | ||
| Donor type | Cord blood | 201 (9%) | 33 (11%) | <.001 |
| Matched related | 729 (34%) | 60 (19%) | ||
| Mismatched related | 143 (7%) | 28 (9%) | ||
| Matched unrelated | 844 (39%) | 168 (54%) | ||
| Mismatched unrelated | 238 (11%) | 25 (8%) | ||
| Donor CMV serostatus | Negative | 1028 (48%) | 145 (46%) | .836 |
| Positive | 977 (45%) | 148 (47%) | ||
| Unknown | 150 (7%) | 21 (7%) | ||
| Stem cell source | Bone marrow | 405 (19%) | 19 (6%) | <.001 |
| Cord blood | 201 (9%) | 33 (11%) | ||
| Peripheral blood stem cells | 1549 (72%) | 262 (83%) | ||
| Conditioning regimen | Myeloablative | 1449 (67%) | 211 (67%) | .988 |
| Nonmyeloablative | 706 (33%) | 103 (33%) | ||
| GVHD prophylaxis | CNI + MMF | 822 (38%) | 57 (18%) | <.001 |
| CNI + MTX | 962 (45%) | 113 (36%) | ||
| PT-Cy | 143 (7%) | 68 (22%) | ||
| Sirolimus based | 138 (6%) | 74 (24%) | ||
| Other | 90 (4%) | 2 (1%) | ||
| Antithymocyte globulin | No | 1966 (91%) | 302 (96%) | .003 |
| Yes | 189 (9%) | 12 (4%) | ||
| Ex vivo TCD or alemtuzumab | No | 2079 (96%) | 298 (95%) | .17 |
| Yes | 76 (4%) | 16 (5%) | ||
| Grade 3-4 acute GVHD before day 100 | No | 1890 (88%) | 252 (80%) | <.001 |
| Yes | 265 (12%) | 62 (20%) | ||
| Any cGVHD | No | 967 (45%) | 164 (52%) | .015 |
| Yes | 1188 (55%) | 150 (48%) | ||
| CMV disease before day 100 | No | 2036 (94%) | 312 (99%) | <.001 |
| Yes | 119 (6%) | 2 (1%) | ||
| Viremia before day 100 | No | 600 (28%) | 146 (46%) | <.001 |
| Low risk | 1132 (53%) | 158 (50%) | ||
| High risk | 423 (20%) | 10 (3%) | ||
| Lymphocyte count at day 100 | <300 cells per mm3 | 242 (11%) | 50 (16%) | .016 |
| ≥300 cells per mm3 | 1913 (89%) | 264 (84%) |
| Variables . | Categories . | PET cohort (n = 2155) . | LET cohort (n = 314) . | P value . |
|---|---|---|---|---|
| Age at transplant, y | Median (range) | 48.9 (0.1-80.9) | 55.7 (18.6-78.2) | <.001 |
| Age at transplant, y | 0-11 | 199 (9%) | 0 (0%) | <.001 |
| 12-17 | 132 (6%) | 0 (0%) | ||
| 18+ | 1824 (85%) | 314 (100%) | ||
| Donor age at transplant, y | Median (range) | 36.2 (0.2-78.0) | 31.1 (17.1-72.2) | <.001 |
| Sex | Female | 1009 (47%) | 148 (47%) | .917 |
| Male | 1146 (53%) | 166 (53%) | ||
| Race | White | 1721 (80%) | 250 (80%) | .079 |
| American Indian or Alaska Native | 48 (2%) | 4 (1%) | ||
| Asian | 186 (9%) | 37 (12%) | ||
| Black or African American | 58 (3%) | 10 (3%) | ||
| Native Hawaiian or other Pacific Islander | 32 (1%) | 6 (2%) | ||
| Multiple | 54 (3%) | 6 (2%) | ||
| Unknown | 56 (3%) | 1 (0%) | ||
| Underlying disease | Acute lymphoblastic leukemia | 284 (13%) | 51 (16%) | <.001 |
| Acute myeloid leukemia/myelodysplastic syndrome | 1045 (48%) | 177 (56%) | ||
| Chronic lymphoid malignancies | 375 (17%) | 11 (4%) | ||
| Chronic myeloid malignancies | 258 (12%) | 57 (18%) | ||
| Nonmalignant diseases | 180 (8%) | 18 (6%) | ||
| Other | 13 (1%) | 0 (0%) | ||
| Number of prior transplants | 1 | 1907 (88%) | 304 (97%) | <.001 |
| >1 | 248 (12%) | 10 (3%) | ||
| Donor type | Cord blood | 201 (9%) | 33 (11%) | <.001 |
| Matched related | 729 (34%) | 60 (19%) | ||
| Mismatched related | 143 (7%) | 28 (9%) | ||
| Matched unrelated | 844 (39%) | 168 (54%) | ||
| Mismatched unrelated | 238 (11%) | 25 (8%) | ||
| Donor CMV serostatus | Negative | 1028 (48%) | 145 (46%) | .836 |
| Positive | 977 (45%) | 148 (47%) | ||
| Unknown | 150 (7%) | 21 (7%) | ||
| Stem cell source | Bone marrow | 405 (19%) | 19 (6%) | <.001 |
| Cord blood | 201 (9%) | 33 (11%) | ||
| Peripheral blood stem cells | 1549 (72%) | 262 (83%) | ||
| Conditioning regimen | Myeloablative | 1449 (67%) | 211 (67%) | .988 |
| Nonmyeloablative | 706 (33%) | 103 (33%) | ||
| GVHD prophylaxis | CNI + MMF | 822 (38%) | 57 (18%) | <.001 |
| CNI + MTX | 962 (45%) | 113 (36%) | ||
| PT-Cy | 143 (7%) | 68 (22%) | ||
| Sirolimus based | 138 (6%) | 74 (24%) | ||
| Other | 90 (4%) | 2 (1%) | ||
| Antithymocyte globulin | No | 1966 (91%) | 302 (96%) | .003 |
| Yes | 189 (9%) | 12 (4%) | ||
| Ex vivo TCD or alemtuzumab | No | 2079 (96%) | 298 (95%) | .17 |
| Yes | 76 (4%) | 16 (5%) | ||
| Grade 3-4 acute GVHD before day 100 | No | 1890 (88%) | 252 (80%) | <.001 |
| Yes | 265 (12%) | 62 (20%) | ||
| Any cGVHD | No | 967 (45%) | 164 (52%) | .015 |
| Yes | 1188 (55%) | 150 (48%) | ||
| CMV disease before day 100 | No | 2036 (94%) | 312 (99%) | <.001 |
| Yes | 119 (6%) | 2 (1%) | ||
| Viremia before day 100 | No | 600 (28%) | 146 (46%) | <.001 |
| Low risk | 1132 (53%) | 158 (50%) | ||
| High risk | 423 (20%) | 10 (3%) | ||
| Lymphocyte count at day 100 | <300 cells per mm3 | 242 (11%) | 50 (16%) | .016 |
| ≥300 cells per mm3 | 1913 (89%) | 264 (84%) |
High-risk viremia is defined as PCR ≥1000 IU/mL or ≥10 antigen-positive cells; low-risk viremia as PCR <1000 IU/mL or <10 antigen-positive cells.
CNI, calcineurin inhibitors; IST, immunosuppressive treatment; MMF, mycophenolate mofetil; MTX, methotrexate; TCD, T-cell depletion.